Selective neuroendocrine effects of low-dose haloperidol in normal adult men
- PMID: 1273208
- DOI: 10.1007/BF00735811
Selective neuroendocrine effects of low-dose haloperidol in normal adult men
Abstract
The neuroendocrine effects of haloperidol, usually reported as side effects of this drug when given in antipsychotic doses, have not been systematically investigated. In the present study five normal adult men were administered saline and two doses of of haloperidol (0.25 mg, 0.5 mg) intramuscularly in a double-blind randomized block design. The anterior pituitary hormones GH, LH, FSH, and PRL were measured in blood samples taken every 20 min for several hours thereafter. The low doses of haloperidol used have been shown by others to alter the human EEG; in our subjects these doses produced no objective or subjective clinical effects. There were no drug related changes in GH, LH, or FSH. PRL, however, showed a prompt, statistically significant, dose-related increase in plasma levels, with a return to baseline with 5 h. Haloperidol has strong dopamine-blocking effects, and the hypothalamic inhibitory mechanism for PRL release is believed to be dopamine-mediated. The results of this study suggest that haloperidol may have utility in low doses primarily for its hypothalamic neuroendocrine effects, and that dose-related PRL release may be a useful paradigm for comparing dopamine-blocking antipsychotic agents in humans.
Similar articles
-
Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.Neuroendocrinology. 1976;20(2):121-35. doi: 10.1159/000122476. Neuroendocrinology. 1976. PMID: 958594
-
Prolactin-related testosterone secretion in normal adult men.J Clin Endocrinol Metab. 1976 Jan;42(1):112-6. doi: 10.1210/jcem-42-1-112. J Clin Endocrinol Metab. 1976. PMID: 1249179 Clinical Trial.
-
Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro.Neuroendocrinology. 1992 Dec;56(6):871-80. doi: 10.1159/000126319. Neuroendocrinology. 1992. PMID: 1369597
-
Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the control of prolactin, growth hormone and gonadotropin secretion in prepubertal rats.J Endocrinol. 1999 Sep;162(3):417-24. doi: 10.1677/joe.0.1620417. J Endocrinol. 1999. PMID: 10467233
-
Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man.J Clin Endocrinol Metab. 1978 Aug;47(2):372-8. doi: 10.1210/jcem-47-2-372. J Clin Endocrinol Metab. 1978. PMID: 45463 Clinical Trial.
Cited by
-
Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?J Neural Transm Gen Sect. 1993;92(2-3):213-20. doi: 10.1007/BF01244880. J Neural Transm Gen Sect. 1993. PMID: 7690232
-
Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men.Psychopharmacology (Berl). 1979 Mar 14;61(1):17-24. doi: 10.1007/BF00426804. Psychopharmacology (Berl). 1979. PMID: 108715 Clinical Trial.
-
Does metergoline selectively attenuate 5-HT mediated prolactin release?Psychopharmacology (Berl). 1991;105(1):129-31. doi: 10.1007/BF02316875. Psychopharmacology (Berl). 1991. PMID: 1745704
-
Lithium increases 5-HT-mediated prolactin release.Psychopharmacology (Berl). 1989;99(2):276-81. doi: 10.1007/BF00442822. Psychopharmacology (Berl). 1989. PMID: 2508166
-
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.Psychopharmacology (Berl). 2006 Mar;185(1):11-8. doi: 10.1007/s00213-005-0279-x. Epub 2006 Jan 24. Psychopharmacology (Berl). 2006. PMID: 16432682 Clinical Trial.